BioPharm International-11-01-2007

Features

November 01, 2007

An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.

Columns and Departments

November 01, 2007

The biopharmaceutical sector can look forward to a financially flush venture funding environment in 2008

Columns and Departments

November 01, 2007

The challenge is not in coming up with a list of activities to discard, but in finding a feasible way to stop doing them.

Columns and Departments

November 01, 2007

Congress postpones debate on follow-on biologics while adopting new policies likely to reshape drug development

Features

November 01, 2007

Contrary to popular belief, the out-of-specification problem started years before the Barr Decision.

Columns and Departments

November 01, 2007

A true visionary leadership is required to drive the progress of operational excellence programs in biopharmaceutical organizations

Columns and Departments

November 01, 2007

CMOs must take a proactive approach to ensure the availability of local talent

Columns and Departments

November 01, 2007

Biotechnology is definitely a hot topic in China-the country's administrators recently identified it as a "cornerstone of China's national economy by 2020." But most realize that getting there will require a better trained, specialized workforce than currently exists. The Chinese government has been pumping money into life sciences education as part of its plan to achieve a global biotechnological presence over the next 15 years.

The industry needs a clear regulatory pathway for the approval of biosimilars.